<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2014413</article-id><article-id pub-id-type="pmcid-ver">PMC2014413.1</article-id><article-id pub-id-type="pmcaid">2014413</article-id><article-id pub-id-type="pmcaiid">2014413</article-id><article-id pub-id-type="pmid">11069437</article-id><article-id pub-id-type="doi">10.1046/j.1365-2125.2000.00272.x</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacokinetics</subject></subj-group></article-categories><title-group><article-title>Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Foster</surname><given-names initials="DJR">David J R</given-names></name><xref ref-type="aff" rid="au1">l</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Somogyi</surname><given-names initials="AA">Andrew A</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dyer</surname><given-names initials="KR">Kyle R</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>White</surname><given-names initials="JM">Jason M</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bochner</surname><given-names initials="F">Felix</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au3">3</xref></contrib><aff id="au1"><label>l</label><institution>Department of Clinical and Experimental Pharmacology, University of Adelaide</institution><addr-line>Adelaide, 5005, Australia</addr-line></aff><aff id="au2"><label>2</label><institution>Department of Psychology, University of Adelaide</institution><addr-line>Adelaide 5005, Australia</addr-line></aff><aff id="au3"><label>3</label><institution>Department of Clinical Pharmacology, Royal Adelaide Hospital</institution><addr-line>Adelaide 5000, Australia</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Correspondence: David J. R. Foster, Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide 5005, South Australia. Work Tel.: + 61 88303 5985; Fax: + 61 88224 0685; E-mail: <email>david.foster@adelaide.edu.au</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2000</year></pub-date><volume>50</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">151552</issue-id><fpage>427</fpage><lpage>440</lpage><history><date date-type="received"><day>01</day><month>2</month><year>2000</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2001</year></date></event><event event-type="pmc-live"><date><day>14</day><month>01</month><year>2008</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-15 03:25:14.360"><day>15</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2000 Blackwell Science Ltd</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bcp0050-0427.pdf"/><abstract><sec><title>Aims</title><p>To investigate the steady-state pharmacokinetics of (R)- and (S)-methadone in a methadone maintenance population.</p></sec><sec><title>Methods</title><p>Eighteen patients recruited from a public methadone maintenance program underwent an interdosing interval pharmacokinetic study. Plasma and urine samples were collected and analysed for methadone and its major metabolite (EDDP) using stereoselective h.p.l.c. Methadone plasma protein binding was examined using ultrafiltration, and plasma &#945;<sub>1</sub>-acid glycoprotein concentrations were quantified by radial immunoassay.</p></sec><sec><title>Results</title><p>(R)-methadone had a significantly (<italic toggle="yes">P</italic> &lt; 0.05) greater unbound fraction (mean 173%) and total renal clearance (182%) compared with (S)-methadone, while maximum measured plasma concentrations (83%) and apparent partial clearance of methadone to EDDP (76%) were significantly (<italic toggle="yes">P</italic> &lt; 0.001) lower. When protein binding was considered (R)-methadone plasma clearance of the unbound fraction (59%) and apparent partial intrinsic clearance to EDDP (44%) were significantly (<italic toggle="yes">P</italic> &lt; 0.01) lower than for (S)-methadone, while <inline-formula><mml:math id="M1" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mi>&#964;</mml:mi></mml:mrow><mml:mrow><mml:mi>SS</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> (167%) was significantly (<italic toggle="yes">P</italic> &lt; 0.001) greater. There were no significant (<italic toggle="yes">P</italic> &gt; 0.2) differences between the methadone enantiomers for <inline-formula><mml:math id="M2" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>AUC</mml:mi></mml:mrow><mml:mrow><mml:mi>&#964;</mml:mi></mml:mrow><mml:mrow><mml:mi>SS</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> steady-state plasma clearance, trough plasma concentrations and unbound renal clearance. Patients excreted significantly (<italic toggle="yes">P</italic> &lt; 0.0001) more (R)-methadone and (S)-EDDP than the corresponding enantiomers. Considerable interindividual variability was observed for the pharmacokinetic parameters, with coefficients of variation of up to 70%.</p></sec><sec><title>Conclusions</title><p>Steady-state pharmacokinetics of unbound methadone are stereoselective, and there is large interindividual variability consistent with CYP3A4 mediated metabolism to the major metabolite EDDP; the variability did not obscure a significant dose-plasma concentration relationship. Stereoselective differences in the pharmacokinetics of methadone may have important implications for pharmacokinetic-pharmacodynamic modelling but is unlikely to be important for therapeutic drug monitoring of methadone, in the setting of opioid dependence.</p></sec></abstract><kwd-group><kwd>2-ethylidene-1</kwd><kwd>5-dimethyl-3</kwd><kwd>3-diphenylpyrrolidine</kwd><kwd>drug dependence</kwd><kwd>metabolism</kwd><kwd>methadone</kwd><kwd>pharmacokinetics</kwd><kwd>protein binding</kwd><kwd>stereoselectivity</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>